- Home
- MNPR vs GLU Comparison
MNPR vs GLU Comparison
Compare MNPR & GLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- GLU
- Stock Information
- Founded
- MNPR 2014
- GLU 2004
- Country
- MNPR United States
- GLU United States
- Employees
- MNPR N/A
- GLU N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- GLU Finance/Investors Services
- Sector
- MNPR Health Care
- GLU Finance
- Exchange
- MNPR Nasdaq
- GLU Nasdaq
- Market Cap
- MNPR 113.5M
- GLU 99.0M
- IPO Year
- MNPR 2019
- GLU N/A
- Fundamental
- Price
- MNPR $30.68
- GLU $16.00
- Analyst Decision
- MNPR Strong Buy
- GLU
- Analyst Count
- MNPR 3
- GLU 0
- Target Price
- MNPR $27.33
- GLU N/A
- AVG Volume (30 Days)
- MNPR 93.6K
- GLU 12.4K
- Earning Date
- MNPR 11-08-2024
- GLU 01-01-0001
- Dividend Yield
- MNPR N/A
- GLU 8.60%
- EPS Growth
- MNPR N/A
- GLU N/A
- EPS
- MNPR N/A
- GLU 0.62
- Revenue
- MNPR N/A
- GLU N/A
- Revenue This Year
- MNPR N/A
- GLU N/A
- Revenue Next Year
- MNPR N/A
- GLU N/A
- P/E Ratio
- MNPR N/A
- GLU $22.50
- Revenue Growth
- MNPR N/A
- GLU N/A
- 52 Week Low
- MNPR $1.55
- GLU $11.61
- 52 Week High
- MNPR $38.50
- GLU $15.40
- Technical
- Relative Strength Index (RSI)
- MNPR 76.63
- GLU 40.72
- Support Level
- MNPR $20.16
- GLU $15.93
- Resistance Level
- MNPR $25.97
- GLU $16.48
- Average True Range (ATR)
- MNPR 2.75
- GLU 0.36
- MACD
- MNPR 0.41
- GLU -0.04
- Stochastic Oscillator
- MNPR 90.25
- GLU 9.46
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About GLU Gabelli Global Utility of Beneficial Ownership
Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.